Quick Answer
Karyopharm Therapeutics Inc. reported Stockholders Equity of -$292.93 million for fiscal year 2025.
Karyopharm Therapeutics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$292.93M | -57.5% |
| 2024 | -$186.02M | -36.6% |
| 2023 | -$136.21M | -717.8% |
| 2022 | -$16.66M | +79.1% |
| 2021 | -$79.67M | -257.6% |
| 2020 | $50.55M | +1.6% |
| 2019 | $49.77M | -72.8% |
| 2018 | $183.17M | +41.5% |
| 2017 | $129.46M | -20.2% |
| 2016 | $162.24M | -18.2% |
| 2015 | $198.37M | -4.1% |
| 2014 | $206.79M | +33.5% |
| 2013 | $154.93M | +655.8% |
| 2012 | -$27.88M | -120.4% |
| 2011 | -$12.65M | -432.4% |
| 2010 | -$2.38M | -1227.4% |
| 2009 | -$179.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$269.26M | -68.7% | -12.7% |
| June 30, 2025 | -$238.93M | -80.8% | -16.0% |
| March 31, 2025 | -$205.88M | -21.9% | -10.7% |
| December 31, 2024 | -$186.02M | -36.6% | -16.5% |
| September 30, 2024 | -$159.65M | -59.0% | -20.8% |
| June 30, 2024 | -$132.14M | -85.5% | +21.8% |
| March 31, 2024 | -$168.96M | -274.0% | -24.0% |
| December 31, 2023 | -$136.21M | -717.8% | -35.7% |
- Karyopharm Therapeutics Inc. showed a decrease of -57.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2009–2025 period, Karyopharm Therapeutics Inc.’s stockholders equity has declined by 163545.8% (from -$179.0 thousand to -$292.93 million).
- The most recent figure is from Karyopharm Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: